Motesanib
Alternative Names: AMG-706; Motesanib diphosphateLatest Information Update: 05 Nov 2023
At a glance
- Originator Amgen
- Developer Amgen; Takeda Bio Development Center
- Class Amides; Antineoplastics; Indoles; Nicotinic acids; Pyridines; Small molecules
- Mechanism of Action Platelet-derived growth factor receptor antagonists; Proto-oncogene protein c-kit inhibitors; Proto-oncogene protein c-ret inhibitors; Vascular endothelial growth factor receptor-1 antagonists; Vascular endothelial growth factor receptor-2 antagonists; Vascular endothelial growth factor receptor-3 antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Breast cancer; Colorectal cancer; Gastrointestinal stromal tumours; Non-small cell lung cancer; Thyroid cancer
Most Recent Events
- 19 May 2015 Discontinued - Phase-III for Non-small cell lung cancer (Combination therapy, First-line therapy, Late-stage disease) in Taiwan, South Korea, Hong Kong, Japan (PO)
- 17 Feb 2015 Takeda Pharmaceuticals terminates the MONET-A phase III trial in Non-small cell lung cancer (advanced disease, combination therapy) in Japan, South Korea, Taiwan, Hong Kong
- 01 Dec 2012 Amgen completes a phase II trial in Gastrointestinal stromal tumours in Japan (NCT00254267)